Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF3108 in advanced solid tumors
NCT06019013Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLF3108 in solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 24 months, Maximum Tolerated Dose at 24 months and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
QLF3108
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06019013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019013.